Key Highlights
- Pfizer spent only 18% of its revenue on R&D in 2024.
- 27% of Pfizer's revenue went to shareholders through dividends and debt repayment.
- Trump's assertion that other countries are to blame for high U. S. drug prices is challenged.
- The article emphasizes pharmaceutical companies as the primary cause of high drug prices.



